A Translational Quantitative Systems Pharmacology Model for CD3 Bispecific Molecules: Application to Quantify T Cell-Mediated Tumor Cell Killing by P-Cadherin LP DART®
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1550-7416
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
A Translational Quantitative Systems Pharmacology Model for CD3 Bispecific Molecules: Application to Quantify T Cell-Mediated Tumor Cell Killing by P-Cadherin LP DART® ; volume:21 ; number:4 ; day:22 ; month:5 ; year:2019 ; pages:1-16 ; date:7.2019
The AAPS journal / American Association of Pharmaceutical Scientists ; 21, Heft 4 (22.5.2019), 1-16, 7.2019
- Creator
-
Betts, Alison
Haddish-Berhane, Nahor
Shah, Dhaval K.
Graaf, Piet H. van der
Barletta, Frank
King, Lindsay
Clark, Tracey
Kamperschroer, Cris
Root, Adam
Hooper, Andrea
Chen, Xiaoying
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1208/s12248-019-0332-z
- URN
-
urn:nbn:de:101:1-2019111413204089349954
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:23 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Betts, Alison
- Haddish-Berhane, Nahor
- Shah, Dhaval K.
- Graaf, Piet H. van der
- Barletta, Frank
- King, Lindsay
- Clark, Tracey
- Kamperschroer, Cris
- Root, Adam
- Hooper, Andrea
- Chen, Xiaoying
- SpringerLink (Online service)
Other Objects (12)
Bispecific antibodies promote natural killer cell-mediated elimination of HIV-1 reservoir cells
Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity
T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
Inhibition of T cell-mediated inflammation in uveitis by a novel anti-CD3 antibody
Engineered allogeneic T cells decoupling T-cell-receptor and CD3 signalling enhance the antitumour activity of bispecific antibodies
A gB/CD3 bispecific BiTE antibody construct for targeting Human Cytomegalovirus-infected cells
Molecular insights into recognition of GUCY2C by T-cell engaging bispecific antibody anti-GUCY2CxCD3
T-cell surveillance of therapy-induced senescent lymphoma cells in the presence of anti-CD19/CD20 × CD3 bispecific antibodies
A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells
AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy
Bispecific antibodies promote natural killer cell-mediated elimination of HIV-1 reservoir cells
Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity
T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
Inhibition of T cell-mediated inflammation in uveitis by a novel anti-CD3 antibody
Engineered allogeneic T cells decoupling T-cell-receptor and CD3 signalling enhance the antitumour activity of bispecific antibodies
A gB/CD3 bispecific BiTE antibody construct for targeting Human Cytomegalovirus-infected cells
Molecular insights into recognition of GUCY2C by T-cell engaging bispecific antibody anti-GUCY2CxCD3
T-cell surveillance of therapy-induced senescent lymphoma cells in the presence of anti-CD19/CD20 × CD3 bispecific antibodies
A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells
AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy
Bispecific antibodies promote natural killer cell-mediated elimination of HIV-1 reservoir cells
Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity
T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
Inhibition of T cell-mediated inflammation in uveitis by a novel anti-CD3 antibody
Engineered allogeneic T cells decoupling T-cell-receptor and CD3 signalling enhance the antitumour activity of bispecific antibodies
A gB/CD3 bispecific BiTE antibody construct for targeting Human Cytomegalovirus-infected cells
Molecular insights into recognition of GUCY2C by T-cell engaging bispecific antibody anti-GUCY2CxCD3
T-cell surveillance of therapy-induced senescent lymphoma cells in the presence of anti-CD19/CD20 × CD3 bispecific antibodies
A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells